Worldwide on Shortwave radio, streaming and satellite
|business Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis PR Newswire Asia|
Anti-ADAMTS5 Nanobody program is Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain. Merck receives upfront payment of € 50 million with the potential of receiving a further € 400 million related to delivering on certain development and commercial milestones.
Posted: 2020-10-06 15:06:00
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.
You can also reach us via Skype